Literature DB >> 3570061

Radical reirradiation for recurrent or second primary carcinoma of the female reproductive tract.

A H Russell, W J Koh, K Markette, K J Russell, J M Cain, H K Tamimi, B E Greer, D C Figge.   

Abstract

Twenty-five women have been treated with a second course of irradiation for recurrent cancer or a second primary carcinoma arising within a previously irradiated pelvic volume. Fourteen patients have been rendered cancer-free (56%) with follow-up ranging from 10 to 61 months. Three of these patients have died of intercurrent disease. Seven of these patients have experienced major complications (50%), necessitating surgical intervention in three cases. The rationale for reirradiation and techniques of retreatment are discussed. Prognostic factors are analyzed and criteria for patient selection are identified.

Entities:  

Mesh:

Year:  1987        PMID: 3570061     DOI: 10.1016/0090-8258(87)90297-6

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Proton Therapy for Vaginal Reirradiation.

Authors:  Yun Rose Li; Maura Kirk; Lilie Lin
Journal:  Int J Part Ther       Date:  2016-12-30

2.  Salvage interstitial brachytherapy based on computed tomography for recurrent cervical cancer after radical hysterectomy and adjuvant radiation therapy: case presentations and introduction of the technique.

Authors:  Zhong-Shan Liu; Jie Guo; Yang-Zhi Zhao; Xia Lin; Bin Chen; Ming Zhang; Jiang-Ming Li; Xiao-Jun Ren; Bing-Ya Zhang; Tie-Jun Wang
Journal:  J Contemp Brachytherapy       Date:  2016-10-25

3.  Permanent interstitial re-irradiation with Au-198 seeds in patients with post-radiation locally recurrent uterine carcinoma.

Authors:  Kaori Okazawa; Keiko Yuasa-Nakagawa; Ryo-Ichi Yoshimura; Hitoshi Shibuya
Journal:  J Radiat Res       Date:  2012-10-15       Impact factor: 2.724

4.  Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy.

Authors:  T Ota; N Takeshima; T Tabata; K Hasumi; K Takizawa
Journal:  Br J Cancer       Date:  2008-10-21       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.